Brief: Eagle Pharmaceuticals Announces FDA Maintains Prioritization Of ANDA For Vasopressin
24/06/2021 11:56
June 24 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS ANNOUNCES FDA MAINTAINS
PRIORITIZATION OF
ANDA FOR VASOPRESSIN
* EAGLE PHARMACEUTICALS - ASSIGNED GDUFA DATE OF DECEMBER
15,
2021, AND EXPECTS COMMERCIAL LAUNCH PRIOR TO YEAR-END
Source text for Eikon: ID:nBw57Ql12a
Further company coverage: EGRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq